Vaccine effectiveness in patients admitted for influenza during the 2023-2024 season

被引:0
|
作者
Martinez, Christian Ruzafa [1 ,2 ,3 ]
Valero, Salvador [1 ,2 ,3 ]
Villalba, Eva Garcia [1 ,2 ,3 ]
Tomas, Cristina [1 ,2 ,3 ]
Munoz, Angeles [1 ,2 ,3 ]
Alcaraz, Antonia [1 ,2 ,3 ]
Martinez-Rodriguez, Rodrigo [1 ,2 ,3 ]
Hernandez, Maria Dolores [1 ,2 ,3 ]
Martinez, Maria Isabel [1 ,2 ,3 ]
Vicente, Maria Rosario [4 ]
Westermeyer, Elena Guijarro [1 ,2 ,3 ]
Hipolito, Roman Gonzalez [1 ,2 ,3 ]
Bernal, Enrique [1 ,2 ,3 ]
机构
[1] Hosp Gen Univ Reina Sofia, Secc Enfermedades Infecciosas, Murcia, Spain
[2] Inst Murciano Invest Biosanitaria Pascual Parrilla, Inmunol Microbiol & Enfermedades Infecciosas, Murcia, Spain
[3] Univ Murcia, Fac Med, Dept Med Interna, Murcia, Spain
[4] Hosp Gen Univ Reina Sofia, Serv Microbiol, Murcia, Spain
来源
MEDICINA CLINICA | 2024年 / 163卷 / 12期
关键词
Flu; Vaccine; Effectiveness; Intensive Care; Mortality;
D O I
10.1016/j.medcli.2024.07.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and goal: Vaccination against influenza is widespread worldwide, reducing complications associated with infection. However, the impact of vaccination on mortality/ICU admission in hospitalized patients has been little studied. Material and methods: A retrospective observational study was conducted on 238 patients hospitalized for influenza from October 2023 to January 2024 to evaluate the vaccine's effectiveness in terms of the combined event of ICU admission/mortality during hospitalization. Additionally, the characteristics of vaccinated patients and the existence of bacterial superinfection were analyzed. Cox regression was performed using the SPSS program and the free << R >> software. Results: A total of 238 patients were included. Those vaccinated were older (78.2 f 8.8 vs 69.97 f 16.6 years; P < .001) and were more likely to have hypertension (82.2% vs 56.2%; P < .001), cardiovascular disease (36.6% vs 24.1%; P = .05), chronic bronchopathy (25.7% vs 8.8%; P = .001), or chronic kidney disease (22.8% vs 8.8%; P = 0.005). They had lower levels of CRP (8.39 f 9.55 vs 11.03 f 10.75 mg/dl; P = .05), procalcitonin (0.62 f 1.74 vs 1.67 f 4.57 ng/dl; P = .05), and SOFA scores (1.13 f 0.9 vs 1.39 f 0.97; P = 0.033). 11 patients were admitted to ICU (4.6%) and 11 died (4.6%). Influenza vaccination was associated as a protective factor against ICU admission/mortality in the Cox regression (HR = 0.216; 95% CI: 0.0620.759, P = .017). The presence of bacterial superinfection was similar between vaccinated and unvaccinated patients (63.4% vs 67.9%; P = .556). Conclusions: Influenza vaccination may reduce the probability of ICU admission or death. This effect is likely due to better control of the immune response. We did not observe any relationship with the risk of presenting bacterial superinfection. (c) 2024 Elsevier Espana, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:589 / 594
页数:6
相关论文
共 50 条
  • [1] Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023-2024 Season
    Choi, Yu Jung
    Song, Joon Young
    Wie, Seong-Heon
    Lee, Jacob
    Lee, Jin-Soo
    Jeong, Hye Won
    Eom, Joong Sik
    Sohn, Jang Wook
    Choi, Won Suk
    Nham, Eliel
    Yoon, Jin Gu
    Noh, Ji Yun
    Cheong, Hee Jin
    Kim, Woo Joo
    VACCINES, 2025, 13 (02)
  • [2] Influenza Vaccine for 2023-2024
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1687): : 161 - 166
  • [3] Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season
    Chung, Jessie R.
    Price, Ashley M.
    Zimmerman, Richard K.
    Geffel, Krissy Moehling
    House, Stacey L.
    Curley, Tara
    Wernli, Karen J.
    Phillips, C. Hallie
    Martin, Emily T.
    Vaughn, Ivana A.
    Murugan, Vel
    Scotch, Matthew
    Saade, Elie A.
    Faryar, Kiran A.
    Gaglani, Manjusha
    Ramm, Jason D.
    Williams, Olivia L.
    Walter, Emmanuel B.
    Kirby, Marie K.
    Keong, Lisa M.
    Kondor, Rebecca
    Ellington, Sascha R.
    Flannery, Brendan
    US Flu VE Network Investigators
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [4] Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season
    Gao, Xin
    Sun, Yexiang
    Shen, Peng
    Guo, Jinxin
    Chen, Yunpeng
    Yin, Yueqi
    Liu, Zhike
    Zhan, Siyan
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [5] Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
    Choi, Yu Jung
    Sohn, Jang Wook
    Choi, Won Suk
    Wie, Seong-Heon
    Lee, Jacob
    Lee, Jin-Soo
    Jeong, Hye Won
    Eom, Joong Sik
    Nham, Eliel
    Seong, Hye
    Yoon, Jin Gu
    Noh, Ji Yun
    Song, Joon Young
    Cheong, Hee Jin
    Kim, Woo Joo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (15)
  • [6] Influenza vaccine for 2023-2024 (vol 65, pg 161, 2023)
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1689): : 184 - 184
  • [7] Genomic evolution of influenza during the 2023-2024 season, the johns hopkins health system
    Yunker, Madeline
    Villafuerte, David A.
    Fall, Amary
    Norton, Julie M.
    Abdullah, Omar
    Rothman, Richard E.
    Fenstermacher, Katherine Z. J.
    Morris, C. Paul
    Pekosz, Andrew
    Klein, Eili
    Mostafa, Heba H.
    JOURNAL OF CLINICAL VIROLOGY, 2024, 174
  • [8] Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023-2024 Season, United States
    Tenforde, Mark W.
    Reeves, Emily L.
    Weber, Zachary A.
    Tartof, Sara Y.
    Klein, Nicola P.
    Dascomb, Kristin
    Desilva, Malini B.
    Yang, Duck-Hye
    Grannis, Shaun J.
    Irving, Stephanie A.
    Ong, Toan C.
    Link-Gelles, Ruth
    Salas, S. Bianca
    Sy, Lina S.
    Lewin, Bruno
    Contreras, Richard
    Zerbo, Ousseny
    Fireman, Bruce
    Hansen, John
    Timbol, Julius
    Sheffield, Tamara
    Bride, Daniel
    Arndorfer, Julie
    Vanotterloo, Josh
    Mcevoy, Charlene E.
    Akinsete, Omobosola O.
    Essien, Inih J.
    Dixon, Brian E.
    Rogerson, Colin
    Fadel, William F.
    Duszynski, Thomas
    Naleway, Allison L.
    Barron, Michelle A.
    Rao, Suchitra
    Mayer, David
    Chavez, Catia
    Ball, Sarah W.
    Payne, Amanda B.
    Ray, Caitlin
    Dickerson, Monica
    Neelam, Varsha
    Adams, Katherine
    Flannery, Brendan
    Decuir, Jennifer
    Garg, Shikha
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [9] Antiviral Drugs for Influenza for 2023-2024
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1689): : 177 - 182
  • [10] Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024
    Abou Chakra, Claire Nour
    Blanquart, Francois
    Vieillefond, Vincent
    Enouf, Vincent
    Visseaux, Benoit
    Haim-Boukobza, Stephanie
    Josset, Laurence
    Rameix-Welti, Marie-Anne
    Lina, Bruno
    Nunes, Marta C.
    Bal, Antonin
    EMERGING MICROBES & INFECTIONS, 2025, 14 (01)